Secondary Hyperparathyroidism In Chronic Kidney Disease: Mechanism Of Development

This study explores the mechanisms of secondary hyperparathyroidism (SHPT) development in chronic kidney disease (CKD) and its implications. SHPT arises due to chronic hypocalcemia and is exacerbated by disturbances in calcium-phosphorus metabolism and vitamin D deficiency. A literature review methodology was used, analyzing peer-reviewed studies to understand SHPT's pathophysiology, diagnostic markers, and treatment strategies. Findings indicate that SHPT results in elevated parathyroid hormone (PTH) levels, causing systemic skeletal damage, vascular calcification, and renal osteodystrophy. Early diagnosis involves assessing serum PTH, calcium, and phosphorus levels, alongside imaging and histomorphometric bone analyses. Treatment includes dietary phosphorus restrictions, phosphate binders, vitamin D analogs, calcimimetics, and parathyroidectomy in severe cases. These interventions aim to regulate PTH levels and prevent complications like fractures and calciphylaxis. This research underscores the necessity of a multidisciplinary approach for effective management and highlights the importance of innovative therapies for long-term SHPT control in CKD patients.